clopidogrel + prasugrel

Clopidogrel + prasugrel refers to the co-administration of two oral thienopyridine antiplatelet agents, each of which is a prodrug requiring hepatic activation, and both act as irreversible antagonists of the P2Y12 ADP receptor on platelets. Their mechanism of action involves inhibition of ADP-induced platelet activation and aggregation by blocking the P2Y12 receptor irreversibly, thus preventing thrombotic events. Both drugs are primarily indicated for reduction of thrombotic cardiovascular events in acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI). There is currently no established clinical use or marketed pharmaceutical product containing both clopidogrel and prasugrel together, as they are typically used as alternatives, not in combination, due to overlapping pharmacology and increased bleeding risk[1][2].

Other names

prasugrel / clopidogrel